高级检索
当前位置: 首页 > 详情页

circPRRC2A promotes angiogenesis and metastasis through epithelial-mesenchymal transition and upregulates TRPM3 in renal cell carcinoma

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Tongji Univ, Shanghai Peoples Hosp 10, Dept Urol, Shanghai, Peoples R China [2]Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA [3]Ninghai Hosp, Branch Shanghai Peoples Hosp 10, Dept Urol, Ningbo, Zhejiang, Peoples R China [4]Shanghai Jiao Tong Univ, Tongren Hosp, Sch Med, Dept Anesthesiol, Shanghai, Peoples R China [5]Capital Med Univ, Beijing Chao Yang Hosp, Dept Pathol, Beijing, Peoples R China [6]Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Sch Med, Dept Urol, Shanghai, Peoples R China [7]Shanghai Jiao Tong Univ, Tongren Hosp, Sch Med, Dept Urol, 1111 Xianxia Rd, Shanghai, Peoples R China
出处:
ISSN:

关键词: circular RNA RCC circPRRC2A lung metastasis therapeutic target

摘要:
Background: Circular RNAs (circRNAs) have been identified as essential regulators in a plethora of cancers. Nonetheless, the mechanistic functions of circRNAs in Renal Cell Carcinoma (RCC) remain largely unknown. Methods: In this study, we aimed to identify novel circRNAs that regulate RCC epithelial-mesenchymal transition (EMT), and to subsequently determine their regulatory mechanisms and clinical significance. Results: circPRRC2A was identified by circRNA microarray and validated by qRT-PCR. The role of circPRRC2A in RCC metastasis was evaluated both in vitro and in vivo. We found that increased expression of circPRRC2A is positively associated with advanced clinical stage and worse survivorship in RCC patients. Mechanistically, our results indicate that circPRRC2A prevents the degradation of TRPM3, a tissue-specific oncogene, mRNA by sponging miR-514a-5p and miR-6776-5p. Moreover, circPRRC2A promotes tumor EMT and aggressiveness in patients with RCC. Conclusions: These findings infer the exciting possibility that circPRRC2A may be exploited as a therapeutic and prognostic target for RCC patients.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 1 区 医学
小类 | 1 区 医学:研究与实验
最新[2025]版:
大类 | 1 区 医学
小类 | 1 区 医学:研究与实验
JCR分区:
出版当年[2018]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Tongji Univ, Shanghai Peoples Hosp 10, Dept Urol, Shanghai, Peoples R China [2]Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
共同第一作者:
通讯作者:
通讯机构: [1]Tongji Univ, Shanghai Peoples Hosp 10, Dept Urol, Shanghai, Peoples R China [6]Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Sch Med, Dept Urol, Shanghai, Peoples R China [7]Shanghai Jiao Tong Univ, Tongren Hosp, Sch Med, Dept Urol, 1111 Xianxia Rd, Shanghai, Peoples R China [*1]Department of Urology, Tongren Hospital of Shanghai JiaoTong University School of Medicine, No.1111 Xianxia Rd, Shanghai, China. [*2]Department of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai [*3]Shanghai First People’s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:23549 今日访问量:0 总访问量:1282 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)